US Patent

US10799481 — Compositions and methods for treating ocular disorders

Method of Use · Assigned to RVL Pharmaceuticals Inc · Expires 2039-12-16 · 14y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions containing oxymetazoline and methods for treating eye disorders related to drooping eyelids, such as ptosis.

USPTO Abstract

The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2849 oxymetazoline-hydrochloride

Patent Metadata

Patent number
US10799481
Jurisdiction
US
Classification
Method of Use
Expires
2039-12-16
Drug substance claim
No
Drug product claim
No
Assignee
RVL Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.